Elderly-onset systemic lupus erythematosus: Prevalence, clinical course and treatment

Drugs and Aging

Volumn 24, Issue 9, 2007, Pages 701-715

  Lazaro, Deana ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; AZATHIOPRINE; CAPSAICIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DIGOXIN; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OXYCODONE; PARACETAMOL; PNEUMOCOCCUS VACCINE; PRASTERONE; PREDNISONE; RITUXIMAB; SALICYLIC ACID; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TRAMADOL; UNINDEXED DRUG;

ACNE; AGED; AGING; ALOPECIA; ASEPTIC MENINGITIS; BLADDER CANCER; BLADDER OBSTRUCTION; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; BREAST TENDERNESS; CARDIOMYOPATHY; CARDIOVASCULAR SYMPTOM; CATARACT; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET RESTRICTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPHORIA; EDEMA; EYE TOXICITY; FALLING; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCOMPLEMENTEMIA; IMMUNOASSAY; INFECTION; INSOMNIA; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS; MENOPAUSE; MYELITIS; MYOPATHY; NAUSEA; NEOPLASM; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; NUTRITIONAL SUPPORT; OILY SKIN; ONSET AGE; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTIVE CLOTHING; RASH; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SEROLOGY; SEROTONERGIC SYNDROME; SIDE EFFECT; SJOEGREN SYNDROME; SPLENECTOMY; STREPTOCOCCUS INFECTION; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VERTIGO; WOUND HEALING;

ADRENAL CORTEX HORMONES; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE;

EID: 34548522473     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724090-00001     Document Type: Review

References (99)

1. Gladman D, Urowitz M. Clinical features of systemic lupus erythematosus. In: Hochberg M, Silman A, Smolen J, et al., editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 417-37
2. Maddison PJ. Systemic lupus erythematosus in the elderly. J Rheumatol Suppl 1987; 14 Suppl. 13: 182-7
3. Ho C, Mok C, Lau C, et al. Late onset systemic lupus erythematosus in Southern Chinese. Ann Rheum Dis 1998; 57: 437-40
4. Boddaert J, Huong D, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine 2004; 83: 348-59
5. Domenech I, Aydintug R, Cervera R, et al. Systemic lupus erythematosus in 50 year olds. Postgrad Med J 1992; 68: 440-4
6. Cervera R, Khamashta M, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 1993; 72: 113-24
7. Hashimoto H, Tsuda H, Hirano T, et al. Differences in clinical and immunological findings of systemic lupus erythematosus related to age. J Rheumatol 1987; 14 (3): 497-501
8. Font J, Pallares L, Cervera R, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis 1991; 50: 702-5
9. Pu S, Luo S, Cheng H, et al. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus 2000; 9: 96-100
10. Salem B, Foad I, Sheon R, et al. Systemic lupus erythematosus in the elderly. Arch Intern Med 1972; 130: 743-6
11. Catoggio L, Skinner R, Smith G, et al. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol 1984; 11 (2): 175-81
12. Gossat DM, Walls RS. Systemic lupus erythematosus in later life. Med J Aust 1982; 1: 297-9
13. Formiga F, Moga I, Pac M, et al. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus 1999; 8: 462-5
14. Voulgari PV, Katsimbri P, Alamanos Y, et al. Gender and age differences in systemic lupus erythematosus: a study of 489 Greek patients with a review of the literature. Lupus 2002; 11: 722-9
15. Hutton CW, Maddison PJ. Systemic lupus erythematosus presenting as polymyalgia rheumatica in the elderly. Ann Rheum Dis 1986; 45: 641-4
16. Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjogrens syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8: 20-3
17. Heckman GA, Papaioannou A, Adachi JD, et al. Systemic lupus erythematosus: presenting as subacute delirium in an 82-year-old woman. J Am Geriatr Soc 2001; 49: 458-61
18. Dennis MS, Byrne EJ, Bendall P. Neuropsychiatric systemic lupus erythematosus in elderly people: a case series. J Neurol Neurosurg Psychiatry 1992; 55: 1157-61
19. Mok CC, Mak A, Chu WP, et al. Long-term survival of Southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine 2005; 84: 218-24
20. Bertoli AM, Alarcon GS, Calvo-Alen J, et al. Systemic lupus erythematosus in a multiethnic US cohort; clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006; 54 (5): 1580-7
21. Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity 2005; 38 (7): 507-18
22. Quiceno GA, Cush JJ. Iatrogenic rheumatic syndromes in the elderly. Rheum Dis Clin North Am 2007; 33 (1): 123-34
23. Ruffatti A, Calligaro A, Del Ross TD, et al. Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics. J Clin Immunol 1990; 10: 300-3
24. Kammer GM, Mishra N. Systemic lupus erythematosus in the elderly. Rheum Dis Clin North Am 2000; 26 (3): 475-92
25. Katz JN, Barrett J, Liang MH, et al. Utilization of rheumatology services by the elderly. Am J Med 1998; 105: 312-8
26. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999; 42: 1785-96
27. Kuhn A, Herrmann M, Kleber S, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006; 54: 939-50
28. Leiba A, Amital H, Gershwin ME, et al. Diet and lupus. Lupus 2001; 10: 246-8
29. Manzi S, Meilahn EN, Raire JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-15
30. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38 (4): 295-301
31. Gagliese L, Melzack R. Chronic pain in elderly people. Pain 1997; 70: 3-14
32. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345 (25): 1801-8
33. Keating GM. Tramadol sustained-release capsules. Drugs 2006; 66 (2): 223-30
34. Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am 2007; 33 (1): 1-31
35. Freedman GM. Chronic pain: clinical management of common causes of geriatric pain. Geriatrics 2002; 57: 36-41
36. Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11: 340-7
37. Østensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001; 10 (3): 135-9
38. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24): 1888-99
39. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329 (7472): 948-53
40. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45 (3): 531-9
41. Morgan A, Clark D. CNS adverse effects of nonsteroidal antiinflammatory drugs: therapeutic implications. CNS Drugs 1998; 9: 281-90
42. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006; 54: 1378-89
43. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44 (10): 2331-7
44. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4
45. Imboden JB. Antimalarial drugs: hydroxychloroquine (Plaquenil) and chloroquine. In: Imboden JB, Hellman DB, Stone JH, editors. Current rheumatology diagnosis and treatment. 2nd ed. New York: The McGraw-Hill Companies, Inc., 2007
46. Marmor MF, Carr RE, Easterbrook M, et.al. Recommendations on screening for chloroquine and hydroxychloroqine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109 (7): 1377-82
47. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-7
48. Orenstein WA. Immunization. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 22nd ed. Philadelphia (PA): W.B. Saunders Company, 2004: 64-74
49. Franco-Paredes C, Diaz-Borjon A, Senger MA, et al. The ever-expanding association between rheumatologic diseases and tuberculosis. Am J Med 2006; 119 (6): 470-7
50. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44 (7): 1496-503
51. Aranow C, Ginzler EM. Treatment of constitutional symptoms, skin, joint, serositis, cardio-pulmonary, hematologic and central nervous system manifestations. In: Hochberg M, Stilman A, Smolen J, et.al, editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 439-48
52. Stein MC. Immunoregulatory drugs. In: Harris Jr ED, Budd RC, Genovese MC, et al., editors. Kelley's textbook of rheumatology. 7th ed. St Louis (MO): Saunders, 2005: 920-39
53. Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38: 640-4
54. Abu-Shakra M, Sheenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001; 10: 152-3
55. Ragab A, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34: 2246-9
56. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30 (9): 951-4
57. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28
58. Krensky AM, Vincenti F, Bennett WM. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL, editor in chief. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc., 2006: 1405-31
59. Miyauchi A, Hiramine C, Tanaka S, et al. Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice flow cytofluorometry analysis. Tohoku J Exp Med 1990; 162 (2): 147-67
60. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
61. Van Vollenhoven DF, Morabito LM, Engleman AG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285-9
62. Rauova L, Likac J, Rovensky J, et al. High-dose intravenous immunoglobulins for lupus nephritis: salvage immunomodulation. Lupus 2001; 10: 209-13
63. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005; 66: 395-402
64. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542-5
65. Dorner T, Kaufman J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74
66. Dooley MA, Ginzler EM. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 2006; 32: 91-102
67. Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986; 11 (1): 102-3
68. Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999; 8: 240-3
69. Bottomley WW, Goodfield M. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995; 133 (2): 311-4
70. Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. Double-blind randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52 (10): 3073-8
71. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheum 1997; 36: 353-9
72. Duong DJ, Spigal T, Moxley RT, et al. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87
73. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000; 39: 218-22
74. Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005; 118 (3): 246-50
75. Houssiau A, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50 (12): 3934-40
76. Haney JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31: 273-98
77. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12: 935-42
78. Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41
79. Mok CC, Lau CS, Wong RWS. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59-62
80. Stojanovich L, Stojanovich R, Kostich V, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12: 3-7
81. Ramos-Casals M, Garcia-Carrasco M, Brito MP, et. al. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 2003; 12: 341-55
82. Chakravarty KK, Al-Hillawi AH, Byron MA, et al. Anticardiolipin antibody associated ischaemic strokes in elderly patients without systemic lupus erythematosus. Age Ageing 1990; 19 (2): 114-8
83. Piette J-C, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195-6
84. Giannouli S, Voulgarelis M, Ziakas P, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006; 65 (2): 144-8
85. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15: 223-31
86. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633-5
87. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14 (10): 856-8
88. Wang SW, Cheng TT. Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporine A: a case report. Lupus 2005; 14 (6): 483-5
89. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 2004; 89 (9): ECR34
90. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15 (4): 223-31
91. Euler HH, Harten P, Zeuner RA, et al. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997; 24: 2153-7
92. Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29: 75-83
93. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004; 240: 286-92
94. Quartuccio L, Sacco S, Franzolini N, et al. Efficacy of cyclosporine-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus 2006; 15: 76-9
95. Moss C, Hamilton PJ. Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. BMJ 1988; 297: 266
96. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12: 630-2
97. Al-Hashimi I. Xerostomia secondary to Sjogren's syndrome in the elderly: recognition and management. Drugs Aging 2005; 22 (11): 887-99
98. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 2042-8
99. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 2980-5